Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 9,794 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced Cancer Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

NCT03911973
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Gedatolisib, Talazoparib
Drug
Lead sponsor
Kari Wisinski
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

NCT01466569
View directory record Official record
Conditions
Solid Tumor of Epithelial Origin, Gastric Cancer
Interventions
AbGn-7
Drug
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Rockledge, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 21, 2026, 2:34 PM EDT
Not yet recruiting Phase 2 Interventional

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

NCT07886905
View directory record Official record
Conditions
Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
Interventions
Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos
Drug · Biological · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT05119296
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Saad A Khan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

NCT00411762
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, PHY906
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00107380
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
78
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 21, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Extra Layer Of Support

NCT03532997
View directory record Official record
Conditions
Advanced Cancer, Palliative Care
Interventions
ELOS
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions
Cemiplimab, Everolimus, Sirolimus, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 21, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00030420
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 21, 2026, 2:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

NCT00908024
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
Interventions
BMS-754807, cetuximab (Erbitux®)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Omaha, Nebraska • Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 21, 2026, 2:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

NCT01926197
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 21, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097
View directory record Official record
Conditions
Prostate Cancer, Advanced Cancer
Interventions
Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

NCT06056024
View directory record Official record
Conditions
Solid Tumor, KRAS Mutation
Interventions
BI 3706674
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

NCT01139346
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
darinaparsin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Lafayette, Indiana • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

First in Human Study of M4344 in Participants With Advanced Solid Tumors

NCT02278250
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor
Interventions
M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

NCT00070096
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

A Study of ABT-414 in Subjects With Solid Tumors

NCT01741727
View directory record Official record
Conditions
Squamous Cell Tumors
Interventions
ABT-414
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 21, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Redirected Auto T Cells for Advanced Myeloma

NCT01352286
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Genetically modified T cells
Genetic
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

NCT05485974
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Interventions
HBI-2438
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Encinitas, California • Glendale, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 21, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

NCT03463460
View directory record Official record
Conditions
Thymic Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate
Other · Biological · Drug
Lead sponsor
Dwight Owen
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 2:34 PM EDT